Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 12/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14420683 | 0.96 | PDK2 (0.40) | PDK2HSD17B1HSD17B2PGRLMNA | |
| SCHEMBL14416486 | 0.96 | PDK2 (0.40) | PDK2HSD17B1HSD17B2PGRLMNA | |
| SCHEMBL17153684 | 0.95 | PDK2 (0.47) | PDK2HSD17B1HSD17B2PGRENPP3 | |
| SCHEMBL29512073 | 0.94 | PDK2 (0.41) | PDK2HSD17B1HSD17B2LMNANPSR1 | |
| SCHEMBL29351177 | 0.94 | PDK2 (0.41) | PDK2HSD17B1HSD17B2LMNANPSR1 | |
| SCHEMBL15473730 | 0.94 | PDK2 (0.41) | PDK2HSD17B1HSD17B2LMNANPSR1 | |
| SCHEMBL17070108 | 0.94 | PDK2 (0.41) | PDK2HSD17B1HSD17B2LMNANPSR1 | |
| SCHEMBL2431947 | 0.94 | PDK2 (0.41) | PDK2HSD17B1HSD17B2LMNANPSR1 | |
| SCHEMBL18906597 | 0.94 | PDK2 (0.41) | PDK2HSD17B1HSD17B2LMNANPSR1 | |
| SCHEMBL14520992 | 0.94 | PDK2 (0.40) | PDK2HSD17B1HSD17B2LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070077450-A1 | Conjugated compounds containing triarylamine structural elements, and their use | LUMINESCENCE TECHNOLOGY CORP. (TW) | 2007-04-05 | — | — | US | disclosed |
| US-20070077450-A1 | Conjugated compounds containing triarylamine structural elements, and their use | LUMINESCENCE TECHNOLOGY CORP. (TW) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070077450-A1 | Conjugated compounds containing triarylamine structural elements, and their use | TIMM9, DCX, INMT | PDK2 3526/4885HSD17B1 2635/4885HSD17B2 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.